Inside the Exploding Market for MDMA Gummies, DMT Vapes, and Gray Market Psychedelics

MDMA gummies. DMT vapes. Mushroom chocolates sold in smoke shops halfway around the world. Long before regulators figured out what legal psychedelics might look like, an unregulated gray-market consumer economy quietly emerged to meet exploding demand.

Psychedelics are more culturally visible and scientifically studied today than at any point in modern history. After two decades of clinical investigation into the potential therapeutic uses of psilocybin and MDMA, both substances received “Breakthrough Therapy” designations from the FDA for specific mental health indications. Combined with mainstream media coverage and endorsements from major cultural figures, psychedelics have increasingly been reframed as potential tools for mental health treatment, spiritual exploration, and personal development rather than the existential social threat portrayed during the height of the War on Drugs.

But while institutions, investors, and policymakers debate what a legal psychedelic future might look like, another market has already arrived.

Professionally branded mushroom chocolates, DMT vape cartridges, LSD mouth sprays, microdose gummies, and other psychedelic consumer products are now widely circulating through gray-market ecosystems around the world. In many places, the products are increasingly visible online and in physical retail environments despite remaining federally illegal across much of the United States.

The result is an emerging psychedelic consumer packaged goods market that looks surprisingly similar to the early days of cannabis commercialization — only moving faster and with even less regulatory clarity.

The Psychedelic Gray Market Is Already Global

As an example of how widespread these products have become, “magic mushroom” and DMT vape products reportedly grew popular enough in parts of Southeast Asia that Malaysian lawmakers moved toward a broad vape ban scheduled for implementation in 2026.

“Among the most popular vape fluids among youths and teenagers today are ‘magic mushroom’ flavours, marketed under various brand names with attractive packaging,” Malaysian assemblyman Datuk Masiung Banah told The Star in February 2025.

“According to a National Poison Centre report, three of these fruit-flavoured vape liquid brands tested contain dimethyltryptamine (DMT), a psychedelic drug diluted and used in electronic cigarette liquids,” Banah continued.

The visibility of psychedelic consumer products increasingly extends well beyond North America.

While traveling through Athens in late 2025, I encountered multiple smokeshops openly displaying Tre House-branded mushroom gummies and chocolates. A week later, similar products appeared again in a retail kiosk in Naples, Italy. In one case, mushroom gummies were sitting in a promotional display directly outside the storefront.

Exactly what compounds are contained in some of these internationally marketed products can be difficult to verify. Industry observers and independent testers have raised concerns that some products marketed as “magic mushroom” edibles may contain synthetic tryptamine analogs or other psychoactive compounds rather than psilocybin mushrooms themselves.

At the same time, products that do appear to contain actual mushrooms remain widely available through online and underground distribution channels.

Officially, much of this market barely exists.

In practice, social media tells a different story.

Search psychedelic-related hashtags on TikTok or Instagram and the scale of the current market becomes impossible to ignore. Content tied to hashtags like #magicmushrooms, #tripreport, and #microdose has accumulated billions of views since TikTok launched in 2016, helping normalize psychedelic aesthetics and products to massive global audiences.

“Psychedelic candies are popping up all over the place these days, though I personally prefer to stay true to the fruit and consume raw mushrooms with intention and reverence,” says music industry executive and mushroom ceremony advocate Edward Crowe.

“But to each his own,” he adds.

That tension increasingly defines the psychedelic CPG conversation.

For some advocates, productized psychedelics represent accessibility, cognitive liberty, and the inevitable next phase of mainstream adoption. Others view branded gummies, disposable DMT vapes, and novelty packaging as fundamentally incompatible with substances they believe require stronger safeguards, ceremonial structure, or intentional use.

Decriminalization, Loopholes, and Legal Ambiguity

Despite widespread visibility, psychedelic consumer products remain federally illegal throughout most of the United States.

Still, a patchwork of decriminalization measures, state-level reforms, religious freedom claims, and legal ambiguity has created enough gray area for underground and semi-public markets to flourish.

Colorado’s Natural Medicine Health Act, for example, decriminalized adult possession and non-commercial sharing of several naturally occurring psychedelic compounds including psilocybin, psilocin, DMT, mescaline excluding peyote, and iboga.

Some facilitators and psychedelic organizations argue that products may legally accompany paid educational, ceremonial, or integration services so long as the substances themselves are not technically being sold directly.

Meanwhile, lesser-known research chemicals and psychedelic analogs are increasingly appearing alongside more familiar substances like psilocybin and DMT.

Compounds such as 2C-B, 3-MMC, and a growing catalog of unscheduled analog molecules have become part of broader underground psychedelic commerce online and in some physical spaces.

Manufacturers have also increasingly marketed “mushroom gummies” and similar products that may contain synthetic psychoactive compounds structurally similar to classic psychedelics rather than naturally occurring psilocybin itself.

The lack of consistent labeling standards or federal oversight has created growing concern around ingredient transparency, potency accuracy, and consumer safety.

Manufacturers have also increasingly marketed “mushroom gummies” and similar products that may contain synthetic psychoactive compounds structurally similar to classic psychedelics rather than naturally occurring psilocybin itself.

The lack of consistent labeling standards or federal oversight has created growing concern around ingredient transparency, potency accuracy, and consumer safety.

“The idea that the government can tell you what you can and can’t put in your body is a relatively recent phenomenon” says Hamilton’s Pharmacopeia producer and Top Tree Herbs owner Soren Shade on a recent Mycopreneur Podcast episode while detailing the evolution of drug prohibition starting with the 1909 Smoking Opium Exclusion Act through the 1971 Controlled Substances Act, which still forms the basis of modern federal drug policy.

The Rise of Psychedelic Product Testing

As the psychedelic product market has expanded, independent testing and verification services have emerged alongside it.

Oakland Hyphae established the first psychedelic testing standards with the Psilocybin Cup in April of 2021, setting the precedent for what is now a wide array of different psychedelic testing cups and competitions. As the mushroom testing industry kicked into high gear with dozens of testing labs and a continuously expanding offering of cups over the last five years, many labs have begun adding testing services for a broader portfolio of psychedelic molecules in accordance with the evolving CPG market.

“We’ve been seeing the surprising absence of 4-AcO-DMT in products for almost a year now alongside the rise of other synthesized compounds like 4-ACO-MET, DIPT, and others that do not convert into psilocin but which are becoming increasingly popular.”

Christopher Pauli, Founder, Tryptomics

“Psychedelic product integrity verification groups like PsiloSafe help to educate on product labeling and consumer awareness about active ingredients and dosing guidelines,” Pauli continues.

“Also, we’ve been seeing the surprising absence of 4-AcO-DMT in products for almost a year now alongside the rise of other synthesized compounds like 4-ACO-MET, DIPT, and others that do not convert into psilocin but which are becoming increasingly popular.”

The publication Wired recently covered a brand of 5-MeO-DMT vapes engineered by former Apple Computer interface designer Bill Atkinson, an advocate for broader psychedelic access and the therapeutic potential of the substance.

The rapid expansion of analog compounds has further complicated efforts to regulate or classify psychedelic consumer products under existing drug policy frameworks.

The Commercial Future of Psychedelics Arrived Early

In many ways, the psychedelic CPG market represents the unintended byproduct of the broader Psychedelic Renaissance itself.

For years, psychedelic advocates, biotech firms, researchers, and media outlets have promoted psychedelics as transformative tools for mental health treatment and personal healing. But while the medical system moves cautiously through clinical trials and regulatory approval, public curiosity has accelerated much faster.

The result is a sprawling underground commercial ecosystem that already resembles a mature consumer industry in many corners of the world.

Unlike LSD during the 1960s, psilocybin mushroom cultivation became radically decentralized after the publication of Psilocybin Magic Mushroom Grower’s Guide in 1976 by Terence and Dennis McKenna under pseudonyms. The rise of internet forums like Erowid and The Shroomery later helped spread cultivation knowledge, extraction methods, underground chemistry techniques, and peer-to-peer information sharing globally.

Today, psychedelics occupy a dramatically different cultural position than they did during the height of the War on Drugs. Public perception has softened. Scientific research has accelerated. Mainstream curiosity has exploded.

And before lawmakers or regulators could fully respond, psychedelic consumer products quietly became a global business.

Exactly what happens next — tighter regulation, broader legalization, aggressive enforcement, or some combination of all three — remains unclear.

What is clear is that the psychedelic consumer packaged goods market is no longer theoretical. It’s already here.

Content Disclaimer: This article is reported analysis based on publicly available information, independent research, and on-the-record sources. Several compounds referenced in this piece are controlled substances under federal law and may be illegal in your jurisdiction. High Times does not endorse or encourage illegal activity of any kind. Readers are encouraged to familiarize themselves with the laws applicable in their jurisdiction before engaging with any psychedelic substances or products.